Table 1.
Clinicopathological characteristics of patients in the training, testing, and external validation cohorts.
| Training set (n=666) | Testing set (n=117) | ExternalValidation set (n=102) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PCR (%)(n=171) | Non-PCR (%)(n=495) | P value | PCR (%)(n=30) | Non-PCR (%)(n=87) | P value | PCR (%)(n=24) | Non-PCR (%)(n=78) | P value | |
| Age, mean(SD), y | 52.77 ± 12.02 | 54.71 ± 11.78 | 0.078 | 53.90 ± 11.71 | 55.38 ± 11.47 | 0.549 | 54.08 ± 11.01 | 57.17 ± 10.37 | 0.182 |
| Sex, No. (%) | 0.849 | 0.376 | 0.081 | ||||||
| Female | 55(32.2) | 154(31.1) | 8(26.7) | 32(36.8) | 12(50.0) | 22(28.2) | |||
| Male | 116(67.8) | 341(68.9) | 22(73.3) | 55(63.2) | 12(50.0) | 56(71.8) | |||
| Clinical T stage | |||||||||
| cT2 | 10(5.9) | 16(3.2) | 0.124 | 2(6.7) | 2(2.3) | 0.271 | 1(4.2) | 0(0.0) | 0.235 |
| cT3 | 113(66.1) | 323(65.3) | 0.926 | 20(66.7) | 55(63.2) | 0.827 | 9(37.5) | 24(30.8) | 0.612 |
| cT4 | 48(28.0) | 156(31.5) | 0.442 | 8(26.6) | 30(34.5) | 0.503 | 14(58.3) | 54(69.2) | 0.333 |
| Clinical N stage | |||||||||
| cN0 | 34(19.9) | 76(15.4) | 0.189 | 5(16.7) | 13(14.9) | 0.777 | 0(0.0) | 18(23.1) | 0.006 |
| cN1 | 86(50.3) | 249(50.3) | 1 | 13(43.3) | 40(46.0) | 0.834 | 17(70.8) | 43(55.1) | 0.236 |
| cN2 | 51(29.8) | 170(34.3) | 0.301 | 12(40.0) | 34(39.1) | 1 | 7(29.2) | 17(21.8) | 0.582 |
| TNM stage | |||||||||
| Stage II | 35(20.5) | 76(15.3) | 0.167 | 5(16.6) | 13(14.9) | 0.777 | 0(0.0) | 18(23.1) | 0.006 |
| Stage III | 136(79.5) | 419(84.7) | 0.124 | 25(83.4) | 74(85.1) | 0.777 | 24(100.0) | 60(76.9) | 0.006 |
| Histological grade | |||||||||
| 1 | 22(12.9) | 55(11.1) | 0.579 | 3(10.0) | 16(18.4) | 0.394 | 1(4.2) | 0(0) | 0.235 |
| 2 | 125(73.1) | 382(77.2) | 0.299 | 22(73.3) | 65(74.7) | 1 | 23(95.8) | 71(91.0) | 0.677 |
| 3 | 24(14.0) | 58(11.7) | 0.421 | 5(16.7) | 6(6.9) | 0.147 | 0(0) | 7(9.0) | 0.194 |
| Patch No. | 102,728 | 18475 | 46599 | ||||||